Revenue Update on Teligent Inc(NASDAQ:TLGT)

Teligent Inc(NASDAQ:TLGT) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $17.14M. Analysts estimated a revenue of $-0.02. Earnings per share were $0.02. Analysts had estimated an EPS of $-0.02.

In a different note, Raymond James said it Initiates Coverage on Teligent Inc, according to a research note issued on Jun 23, 2016. The shares have been rated ‘Strong Buy’ by the firm.

Several Insider Transactions has been reported to the SEC. On Mar 14, 2016, Jason Grenfell-gardner (CEO) purchased 10,500 shares at $4.82 per share price.Also, On Mar 14, 2016, James C Gale (director 10% owner) purchased 15,000 shares at $4.91 per share price.

Teligent Inc. formerly IGI Laboratories Inc. is a specialty generic pharmaceutical company. The Company is engaged in the manufacture and development of topical pharmaceutical over-the-counter (OTC) and cosmetic products. The Company under its label sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company has two platforms for growth: developing manufacturing and marketing a range of generic pharmaceutical products under its label in topical injectable complex and ophthalmic dosage forms and managing its contract manufacturing and formulation services business. The Company’s contract manufacturing and development business includes two services: contract formulation and contract manufacturing. The Company’s products are used in a range of applications such as cosmetics and prescription treatment of conditions such as dermatitis psoriasis and eczema.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Teligent Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Teligent Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.